120041-08-9

Basic information

• Product Name: GADOTERIDOL RELATED COMPOUND A (50 MG) (10-(2-HYDROXYPROPYL)-1,4,7,10-TETRAAZACYCLODODE-CANE-1,4,7-TRIACETIC ACID)
• Synonyms: 2,2',2''-[10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl]triacetic acid;DesgadoliniuM Gadoteridol;Gadoteridol Related CoMpound A;10-(2-Hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid;HP-DO3A;1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-(2-hydroxypropyl)-;GADOTERIDOL RELATED COMPOUND A (50 MG) (10-(2-HYDROXYPROPYL)-1,4,7,10-TETRAAZACYCLODODE-CANE-1,4,7-TRIACETIC ACID);Gadoteridol Related Compound A (50 mg) (10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid)
• CAS NO: 120041-08-9
• Molecular Formula: C17H32N4O7
• Molecular Weight: 404.45858
• Mol File: 120041-08-9.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: GADOTERIDOL RELATED COMPOUND A (50 MG) (10-(2-HYDROXYPROPYL)-1,4,7,10-TETRAAZACYCLODODE-CANE-1,4,7-TRIACETIC ACID)(CAS DataBase Reference)
• NIST Chemistry Reference: GADOTERIDOL RELATED COMPOUND A (50 MG) (10-(2-HYDROXYPROPYL)-1,4,7,10-TETRAAZACYCLODODE-CANE-1,4,7-TRIACETIC ACID)(120041-08-9)
• EPA Substance Registry System: GADOTERIDOL RELATED COMPOUND A (50 MG) (10-(2-HYDROXYPROPYL)-1,4,7,10-TETRAAZACYCLODODE-CANE-1,4,7-TRIACETIC ACID)(120041-08-9)

Safety Data

• Hazardous Substances Data: 120041-08-9(Hazardous Substances Data)

Usage

Uses

Desgadolinium Gadoteridol is an impurity in the synthesis of Gadoteridol (G125900), which is used an MRI contrast chelating agent.

Upstream product

• 114873-37-9 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid 
• 75-56-9 methyloxirane 

Relevant articles and documents

METHOD FOR MANUFACTURING CALTERIDOL

It is disclosed a method for preparing calteridol used as MRI contrast agents. It provides a method for preparing calteridol comprising: obtaining teridol represented by the following Formula 2 by reacting gadoteridol represented by the following Formula 1 with decomplexing agent; and obtaining calteridol represented by the following Formula 3 by reacting calcium ion with teridol represented by following Formula 2.

Hydrolysis method of tert-butyl ester used in gadolinium contrast agent

The invention provides a hydrolysis method of tert-butyl ester used in a gadolinium contrast agent. The hydrolysis method comprises the following step: hydrolyzing the tert-butyl ester by using a catalyst. The preparation method of the catalyst comprises the following steps: performing a reaction on zirconium dioxide and titanium tetrachloride in the presence of sulfuric acid and water at 60-90 DEG C until a solid is dissolved, adding silicon dioxide for reaction for 1-5 hours, filtering a reaction product and collecting the solid, and washing and roasting the solid. No acid or other substances difficult to remove are introduced into the hydrolysis method, so that the hydrolysis efficiency is high, and the purity of the obtained product is high.

Graphene Oxide Cellular Delivery of Hydrophilic Small Molecules

Unmodified graphene oxide conjugated with hydrophilic small molecules for cellular delivery.